Predictive significance of the proportion of ER-positive or PgR-positive tumor cells in response to neoadjuvant chemotherapy for operable HER2-negative breast cancer

Osako,Tomofumi; Nishimura,Reiki; Okumura,Yasuhiro; Toyozumi,Yasuo; Arima,Nobuyuki

doi:10.3892/etm.2011.359

Predictive significance of the proportion of ER-positive or PgR-positive tumor cells in response to neoadjuvant chemotherapy for operable HER2-negative breast cancer

Authors:
- Tomofumi Osako
- Reiki Nishimura
- Yasuhiro Okumura
- Yasuo Toyozumi
- Nobuyuki Arima
View Affiliations

Affiliations: Department of Breast and Endocrine Surgery, Kumamoto City Hospital, Kumamoto 862-8505, Japan, Department of Clinical Pathology, Kumamoto City Hospital, Kumamoto 862-8505, Japan
Published online on: October 3, 2011 https://doi.org/10.3892/etm.2011.359
Pages: 66-71

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Estrogen receptor (ER) and progesterone receptor (PgR) status are predictive factors for the clinical and pathological response to neoadjuvant chemotherapy for operable breast cancer. However, it remains unclear as to how the proportion of ER-positive or PgR-positive tumor cells affects the response to neoadjuvant chemotherapy. We examined the correlation of the proportion of ER-positive or PgR-positive tumor cells with the clinical and pathological response to neoadjuvant chemotherapy for operable human epidermal growth factor receptor 2 (HER2)-negative breast cancer. From April 2002 to October 2010, 103 patients received neoadjuvant chemotherapy containing epirubicin and taxane in our clinic. A clinical response was observed in 86 (83%) patients, and a pathological complete response (pCR) was observed in 16 (16%) patients. Fourteen (30%) of 46 patients with ER-negative tumors achieved pCR and 15 (26%) of 57 patients with PgR-negative tumors achieved pCR. Patients with more than 30% ER-positive tumor cells or more than 1% PgR-positive tumor cells did not achieve pCR. No significant correlation was observed between pCR and the menopausal status, tumor size, grade and Ki-67 expression. In univariate analysis, pCR was associated with the ER status (p=0.001), PgR status (p=0.0001) and chemotherapy regimens (p=0.03). Multivariate analysis revealed that ER and PgR status were significant factors for pCR, and patients with ER-negative tumors were 18.6 times more likely to achieve pCR than those with greater than or equal to 30% ER-positive tumor cells (p=0.006; 95% confidence interval 2.3-149.9). We demonstrated a predictive significance of the proportion of ER-positive or PgR-positive tumor cells in the response to neoadjuvant chemotherapy for operable HER2-negative breast cancer. ER-negativity (<1%) was a significant predictive factor for achieving pCR in multivariate analysis. Conversely, patients with more than 30% ER-positive tumor cells or more than 1% PgR-positive tumor cells may not achieve pCR.

View Figures

View References

1.	JA Van der HageCJ van de VeldeJP JulienM Tubiana-HulinC VanderveldenL DuchateauPreoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902J Clin Oncol19422442372001
2.	HD BearS AndersonA BrownThe effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from the National Surgical Adjuvant Breast and Bowel Project Protocol B-27J Clin Oncol2141654174200310.1200/JCO.2003.12.005
3.	B FisherJ BryantN WolmarkEffect of preoperative chemotherapy on the outcome of women with operable breast cancerJ Clin Oncol162672268519989704717
4.	A MakrisTJ PowlesSE AshleyA reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancerAnn Oncol911791184199810.1023/A:10084007069499862047
5.	L MauriacG MacGroganA AvrilNeoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-upInstitut Bergonie Bordeaux Groupe Sein (IBBGS) Ann Oncol1047521999
6.	R RouzierCM PerouWF SymmansBreast cancer molecular subtypes respond differently to preoperative chemotherapyClin Cancer Res1156785685200510.1158/1078-0432.CCR-04-242116115903
7.	P RastogiSJ AndersonHD BearPreoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27J Clin Oncol26778785200810.1200/JCO.2007.15.023518258986
8.	E ThomasFA HolmesTL SmithThe use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trialJ Clin Oncol2222942302200410.1200/JCO.2004.05.207
9.	G BonadonnaP ValagussaC BrambillaPrimary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer InstituteJ Clin Oncol169310019989440728
10.	HM KuererLA NewmanTL SmithClinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapyJ Clin Oncol174604691999
11.	A EltahirSD HeysAW HutcheonTreatment of large and locally advanced breast cancers using neoadjuvant chemotherapyAm J Surg175127132199810.1016/S0002-9610(97)00279-19515529
12.	LA CareyR MetzgerEC DeesAmerican Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcomeJ Natl Cancer Inst9711371142200510.1093/jnci/dji20616077072
13.	BT HennessyGN HortobagyiR RouzierOutcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapyJ Clin Oncol2393049311200510.1200/JCO.2005.02.5023
14.	AE RingIE SmithS AshleyLG FulfordSR LakhaniOestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancerBr J Cancer9120122017200410.1038/sj.bjc.6602235
15.	RJ BurcombeA MakrisPI RichmanEvaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancerBr J Cancer92147155200510.1038/sj.bjc.660225615611798
16.	M ColleoniV BagnardiN RotmenszIncreasing steroid hormone receptor expression defines breast cancer subtypes non-responsive to preoperative chemotherapyBreast Cancer Res Treat116359369200910.1007/s10549-008-0223-y
17.	M ColleoniG VialeD ZahriehExpression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapyAnn Oncol19465472200810.1093/annonc/mdm50917986623
18.	M ColleoniG VialeD ZahriehChemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatmentClin Cancer Res1066226628200410.1158/1078-0432.CCR-04-038015475452
19.	ME HammondDF HayesM DowsettAmerican Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerJ Clin Oncol2827842795201010.1200/JCO.2009.25.6529
20.	AU BuzdarNK IbrahimD FrancisSignificantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancerJ Clin Oncol2336763685200510.1200/JCO.2005.07.032
21.	EA EisenhauerP TherasseJ BogaertsNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer45228247200910.1016/j.ejca.2008.10.026
22.	K KaiN ArimaH MiyayamaY YamamotoH IwaseR NishimuraPathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin-docetaxel neoadjuvant chemotherapy: a cohort studyBreast Cancer164248200910.1007/s12282-008-0055-y
23.	JM HarveyGM ClarkCK OsborneDC AllredEstrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancerJ Clin Oncol17147414811999